{"id":938662,"date":"2026-02-20T08:10:52","date_gmt":"2026-02-20T13:10:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/"},"modified":"2026-02-20T08:10:52","modified_gmt":"2026-02-20T13:10:52","slug":"engene-to-participate-in-upcoming-investor-conferences-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/","title":{"rendered":"enGene to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>enGene to Participate in Upcoming Investor Conferences<\/b><\/p>\n<p>BOSTON &amp; MONTREAL&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nenGene Holdings Inc. (Nasdaq: ENGN or \u201cenGene\u201d), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences:<\/p>\n<p><b>Oppenheimer 36th Annual Healthcare Life Sciences Conference<br \/>\n<br \/><\/b><b>Date:<\/b> Thursday, February 26, 2026<br \/>\n<br \/><b>Format:<\/b> Presentation<br \/>\n<br \/><b>Time:<\/b> 1:20 p.m. ET<\/p>\n<p><b>Leerink Partners 2026 Global Healthcare Conference<br \/>\n<br \/><\/b><b>Date: <\/b>Monday, March 9, 2026<br \/>\n<br \/><b>Format:<\/b> Fireside chat<br \/>\n<br \/><b>Time:<\/b> 8:00 a.m. ET<\/p>\n<p><b>Barclays 28<sup>th<\/sup> Annual Global Healthcare Conference<br \/>\n<br \/><\/b><b>Date:<\/b> Tuesday, March 10, 2026<br \/>\n<br \/><b>Format:<\/b> Fireside chat<br \/>\n<br \/><b>Time:<\/b> 9:00 a.m. ET<\/p>\n<p><b>Citizens Life Sciences Conference<br \/>\n<br \/><\/b><b>Date:<\/b> Wednesday, March 11, 2026<br \/>\n<br \/><b>Format:<\/b> Fireside chat<br \/>\n<br \/><b>Time:<\/b> 1:40 p.m. ET<\/p>\n<p>\nA live webcast of these events can be accessed on the &#8220;Events and Presentations\u201d page under the \u201cInvestors\u201d section of the enGene website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.engene.com&amp;esheet=54429363&amp;newsitemid=20260220533113&amp;lan=en-US&amp;anchor=www.engene.com&amp;index=1&amp;md5=7ffbae88b57a62fad59514af5020881a\">www.engene.com<\/a> and will be archived there for 90 days.<\/p>\n<p><b>About enGene<\/b><\/p>\n<p>\nenGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene\u2019s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene\u2019s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.<\/p>\n<p>\nTo learn more, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fengene.com%2F&amp;esheet=54429363&amp;newsitemid=20260220533113&amp;lan=en-US&amp;anchor=enGene.com&amp;index=2&amp;md5=bfe067d3223fcb7e93e741cdea437171\">enGene.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fengene%2F&amp;esheet=54429363&amp;newsitemid=20260220533113&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=1f3bd9cdc08e9354abf4bc9c4e454687\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2Fengene_inc&amp;esheet=54429363&amp;newsitemid=20260220533113&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=d99a32cb7bea0c3c882aeec2f740ed75\">X<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbsky.app%2Fprofile%2Fengeneinc.bsky.social&amp;esheet=54429363&amp;newsitemid=20260220533113&amp;lan=en-US&amp;anchor=BlueSky&amp;index=5&amp;md5=12b406384b74082c6241f17ed79c769b\">BlueSky<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260220533113\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260220533113\/en\/<\/a><\/span><\/p>\n<p>\nFor media:<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@engene.com\">media@engene.com<br \/>\n<\/a><\/p>\n<p>For investor:<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@engene.com\">investors@engene.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Florida Massachusetts United States North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Oncology General Health Health Genetics Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260220533113\/en\/2159786\/3\/enGene_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>enGene to Participate in Upcoming Investor Conferences BOSTON &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; enGene Holdings Inc. (Nasdaq: ENGN or \u201cenGene\u201d), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Format: Presentation Time: 1:20 p.m. ET Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Format: Fireside chat Time: 8:00 a.m. ET Barclays 28th Annual Global Healthcare Conference Date: Tuesday, March 10, 2026 Format: Fireside chat Time: 9:00 a.m. ET Citizens Life Sciences Conference Date: Wednesday, March 11, 2026 Format: Fireside chat Time: 1:40 p.m. ET A live webcast of these events can be accessed on the &#8220;Events and Presentations\u201d page &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;enGene to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-938662","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>enGene to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"enGene to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"enGene to Participate in Upcoming Investor Conferences BOSTON &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; enGene Holdings Inc. (Nasdaq: ENGN or \u201cenGene\u201d), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Format: Presentation Time: 1:20 p.m. ET Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Format: Fireside chat Time: 8:00 a.m. ET Barclays 28th Annual Global Healthcare Conference Date: Tuesday, March 10, 2026 Format: Fireside chat Time: 9:00 a.m. ET Citizens Life Sciences Conference Date: Wednesday, March 11, 2026 Format: Fireside chat Time: 1:40 p.m. ET A live webcast of these events can be accessed on the &#8220;Events and Presentations\u201d page &hellip; Continue reading &quot;enGene to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-20T13:10:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"enGene to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-02-20T13:10:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/\"},\"wordCount\":338,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/\",\"name\":\"enGene to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-02-20T13:10:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"enGene to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"enGene to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/","og_locale":"en_US","og_type":"article","og_title":"enGene to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"enGene to Participate in Upcoming Investor Conferences BOSTON &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; enGene Holdings Inc. (Nasdaq: ENGN or \u201cenGene\u201d), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Format: Presentation Time: 1:20 p.m. ET Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Format: Fireside chat Time: 8:00 a.m. ET Barclays 28th Annual Global Healthcare Conference Date: Tuesday, March 10, 2026 Format: Fireside chat Time: 9:00 a.m. ET Citizens Life Sciences Conference Date: Wednesday, March 11, 2026 Format: Fireside chat Time: 1:40 p.m. ET A live webcast of these events can be accessed on the &#8220;Events and Presentations\u201d page &hellip; Continue reading \"enGene to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-20T13:10:52+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"enGene to Participate in Upcoming Investor Conferences","datePublished":"2026-02-20T13:10:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/"},"wordCount":338,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/","name":"enGene to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-02-20T13:10:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260220533113r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"enGene to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/938662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=938662"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/938662\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=938662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=938662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=938662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}